Vicarious Surgical Inc. (“Vicarious” or “Vicarious Surgical” or the “Company”), a next-generation robotics technology company seeking to improve both cost and efficiency of surgical procedures as well as patient outcomes, today announced that Adam Sachs, Co-Founder and Chief Executive Officer of Vicarious Surgical, will participate in a panel discussion on the future of surgical robots at the Surgical Disruptive Technology Summit
| WALTHAM, Mass., May 27, 2021 /PRNewswire/ -- Vicarious Surgical Inc. (“Vicarious” or “Vicarious Surgical” or the “Company”), a next-generation robotics technology company seeking to improve both cost and efficiency of surgical procedures as well as patient outcomes, today announced that Adam Sachs, Co-Founder and Chief Executive Officer of Vicarious Surgical, will participate in a panel discussion on the future of surgical robots at the Surgical Disruptive Technology Summit in Houston, Texas on June 4, 2021.
Presentation Details Title: Surgical Robotics: The Next 5 Years About Vicarious Surgical Founded in 2014, Vicarious Surgical is a next generation robotics company developing a disruptive technology with the goals of increasing the efficiency of surgical procedures, improving patient outcomes and reducing healthcare costs. The Company’s novel surgical approach uses a combination of proprietary human-like surgical robots and virtual reality to transport surgeons inside the patient to perform minimally invasive surgery. The Company’s technology was granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA), making it the first, and only, surgical robot to receive this designation from the FDA.* Investor Inquiries: Press and Media Inquiries: * As of the date of this press release, Vicarious Surgical is not aware of any surgical robotics company that has announced receiving Breakthrough Designation for a full robotics system.
SOURCE Vicarious Surgical | ||
Company Codes: NYSE:DEH |
View original content to download multimedia:
